← All trials
NCT06087276
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 2, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- Apr 30, 2025
- First posted
- Oct 17, 2023
- Last posted
- Nov 9, 2023
- Enrollment
- 620
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Praxis BiologicsLead sponsor
- Praxis BiologicsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.